Repare Therapeutics Inc. 8-K Report: Key Updates for Investors - February 2025

Based on the provided section of the financial report, here are the key extracted details and insights:

1. Entity Information:

• Company Name: Repare Therapeutics Inc.
• CIK (Central Index Key): 0001808158
• SEC File Number: 001-39335
• Address: 7171 Frederick-Banting, Building 2 Suite 270, St-Laurent, QC, CA, H4S 1Z9
• Phone Number: 857-412-7018

2. Filing Information:

• Type of Filing: 8-K (Current Report)
• Filing Date: February 23, 2025

3. Stock Information:

• Common Shares: No par value
• Ticker Symbol: RPTX
• Exchange: NASDAQ

4. Reporting Structure:

• The report is filed under XBRL (eXtensible Business Reporting Language), which suggests that the company is adhering to modern reporting standards for financial statements.

5. Period Covered:

• Start Date of Reporting Period: February 23, 2025
• End Date of Reporting Period: February 23, 2025
• This indicates that it is a single-day report, possibly detailing a specific event or condition as required by the SEC.

Insights:

• The filing type (8-K) generally indicates that the company is reporting significant events that shareholders should be aware of. It could involve material events such as acquisitions, changes in management, financial performance updates, etc.
• The fact that this is a current report also emphasizes the urgency and relevance of the information contained within for investors and stakeholders.
• Listing on NASDAQ and the provision of a CIK number show that Repare Therapeutics Inc. is a publicly traded company, subjected to regulatory oversight.

This information serves as a snapshot of the company's current status and relevant events as of the specified date, which is crucial for investors and analysts following the company’s performance and developments.